Sally-anne Hulton

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.

Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: May 14, 2025

Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria.

Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 08, 2024

Intrafamilial Disease Heterogeneity in Primary Hyperoxaluria Type 1.

Intrafamilial Disease Heterogeneity in Primary Hyperoxaluria Type 1.

Journal: Kidney international reports

Published: May 06, 2024

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.

Journal: Kidney international reports

Published: December 11, 2023

Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium.

Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium.

Journal: Kidney international reports

Published: May 11, 2023

Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry.

Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry.

Journal: Kidney international reports

Published: January 26, 2022

Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry.

Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry.

Journal: Kidney international reports

Published: September 21, 2021

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: September 11, 2020

Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies.

Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies.

Journal: Pediatric nephrology (Berlin, Germany)

Published: July 24, 2020

Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.

Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.

Journal: Kidney international

Published: December 10, 2018

Primary hyperoxaluria in populations of Pakistan origin: results from a literature review and two major registries.

Primary hyperoxaluria in populations of Pakistan origin: results from a literature review and two major registries.

Journal: Urolithiasis

Published: November 29, 2016

The primary hyperoxalurias: A practical approach to diagnosis and treatment.

The primary hyperoxalurias: A practical approach to diagnosis and treatment.

Journal: International journal of surgery (London, England)

Published: October 12, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026